BR112020015796A2 - nanocomplexos semelhantes a lipídios e usos dos mesmos - Google Patents

nanocomplexos semelhantes a lipídios e usos dos mesmos Download PDF

Info

Publication number
BR112020015796A2
BR112020015796A2 BR112020015796-1A BR112020015796A BR112020015796A2 BR 112020015796 A2 BR112020015796 A2 BR 112020015796A2 BR 112020015796 A BR112020015796 A BR 112020015796A BR 112020015796 A2 BR112020015796 A2 BR 112020015796A2
Authority
BR
Brazil
Prior art keywords
piperazine
fact
ocholb
gfp
lnps
Prior art date
Application number
BR112020015796-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Qiaobing Xu
Yamin Li
Original Assignee
Trustees Of Tufts College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trustees Of Tufts College filed Critical Trustees Of Tufts College
Publication of BR112020015796A2 publication Critical patent/BR112020015796A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A61K49/0047—Green fluorescent protein [GFP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
BR112020015796-1A 2018-02-01 2019-02-01 nanocomplexos semelhantes a lipídios e usos dos mesmos BR112020015796A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862625153P 2018-02-01 2018-02-01
US62/625,153 2018-02-01
PCT/US2019/016362 WO2019152848A1 (en) 2018-02-01 2019-02-01 Lipid-like nanocomplexes and uses thereof

Publications (1)

Publication Number Publication Date
BR112020015796A2 true BR112020015796A2 (pt) 2021-02-09

Family

ID=67478550

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020015796-1A BR112020015796A2 (pt) 2018-02-01 2019-02-01 nanocomplexos semelhantes a lipídios e usos dos mesmos

Country Status (11)

Country Link
US (2) US12133855B2 (cg-RX-API-DMAC7.html)
EP (1) EP3746129A4 (cg-RX-API-DMAC7.html)
JP (2) JP7497045B2 (cg-RX-API-DMAC7.html)
KR (1) KR102904334B1 (cg-RX-API-DMAC7.html)
CN (1) CN111954542A (cg-RX-API-DMAC7.html)
AU (1) AU2019215157B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020015796A2 (cg-RX-API-DMAC7.html)
CA (1) CA3089826A1 (cg-RX-API-DMAC7.html)
IL (1) IL276322B2 (cg-RX-API-DMAC7.html)
MX (1) MX429255B (cg-RX-API-DMAC7.html)
WO (1) WO2019152848A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
IL276322B2 (en) 2018-02-01 2024-12-01 Tufts College Lipid-like nanocomplexes and uses thereof
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
MX2022006854A (es) 2019-12-04 2022-11-30 Orna Therapeutics Inc Composiciones y metodos de arn circular.
JP7716112B2 (ja) * 2020-03-02 2025-07-31 トラスティーズ オブ タフツ カレッジ 免疫細胞へのin vivoでのmRNA送達のためのイミダゾール系合成リピドイド
US20240245805A1 (en) 2020-03-20 2024-07-25 Orna Therapeutics, Inc. Circular rna compositions and methods
KR20230005367A (ko) * 2020-05-04 2023-01-09 트러스티즈 오브 터프츠 칼리지 뇌 전달을 위한 합성 지질-유사 물질
EP4164647A4 (en) * 2020-06-12 2024-07-24 Trustees Of Tufts College Ph-responsive lipidoid nanoparticles for intracellular mrna delivery
KR20230051172A (ko) 2020-07-16 2023-04-17 아퀴타스 테라퓨틱스 인크. 지질 나노 입자에 사용하기 위한 양이온성 지질
IL303434A (en) * 2020-12-07 2023-08-01 Tufts College Lipidoid preparations and methods of using them
JP2024504636A (ja) * 2021-01-15 2024-02-01 トラスティーズ オブ タフツ カレッジ mRNAの標的化送達のための脂質ナノ粒子
CN117769428A (zh) * 2021-04-30 2024-03-26 塔夫茨大学信托人 用于治疗疾病和病症的类脂质纳米颗粒
CN113402404B (zh) 2021-04-30 2022-03-11 苏州科锐迈德生物医药科技有限公司 脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂
CN113387825A (zh) * 2021-06-10 2021-09-14 福州大学 长链烷基酯胺类化合物或含氟长链烷基酯胺类化合物及其公斤级制备方法
AU2022288705A1 (en) 2021-06-10 2023-12-07 Orna Therapeutics, Inc. Circular rna compositions and methods
US20250268828A1 (en) 2021-09-30 2025-08-28 Orna Therapeutics, Inc. Lipid Nanoparticle Compositions for Delivering Circular Polynucleotides
WO2023081526A1 (en) 2021-11-08 2023-05-11 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
CN114163345B (zh) * 2021-12-15 2022-07-26 武汉滨会生物科技股份有限公司 一种可离子化脂质化合物及核酸体外细胞转染试剂
CN114191561B (zh) * 2021-12-15 2022-08-02 武汉滨会生物科技股份有限公司 一种可离子化脂质化合物在核酸药物递送系统中的应用
WO2023114943A2 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
CA3242399A1 (en) * 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Fluorinated cationic lipids for use in lipid nanoparticles
CN116813493B (zh) * 2022-03-21 2026-04-28 苏州科锐迈德生物医药科技有限公司 一种脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂
CN114716355B (zh) * 2022-04-02 2023-09-05 华南理工大学 一种脂质化合物、包含其的组合物及应用
CN114773217B (zh) * 2022-06-20 2022-10-18 深圳市瑞吉生物科技有限公司 用于递送核酸的阳离子脂质化合物和组合物及用途
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
WO2024077232A2 (en) * 2022-10-07 2024-04-11 The Trustees Of The University Of Pennsylvania Compositions and methods for t cell targeted delivery of therapeutic agents and activation of t cells
WO2024102730A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and nanoparticle compositions for delivering polynucleotides
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
TW202428289A (zh) 2022-11-08 2024-07-16 美商歐納醫療公司 環狀rna組合物
CN116063245B (zh) * 2022-12-05 2024-09-10 南开大学 一种中心可降解的mRNA脂质体纳米粒子及其制备方法和应用
KR102758330B1 (ko) * 2023-02-22 2025-01-23 주식회사 서지넥스 황화물을 포함하는 이온화 가능한 지질 및 이를 포함하는 지질나노입자
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
KR102902665B1 (ko) * 2024-11-29 2025-12-22 이화여자대학교 산학협력단 에틸렌글리콜을 포함한 생분해성 이온화 지질 및 이를 이용한 약물 전달용 지질나노입자
CN119320334A (zh) * 2024-12-19 2025-01-17 国家纳米科学中心 具有三维空间结构的可电离脂质化合物及制备方法与应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE682393C (de) 1933-04-14 1939-10-13 I G Farbenindustrie Akt Ges Verfahren zur Herstellung quaternaerer Stickstoffverbindungen
US4275236A (en) 1979-12-26 1981-06-23 Sherex Chemical Company, Inc. Tertiary di-(β-hydroxy organo) amine oxides and their preparation
EP0863749A2 (en) * 1995-11-30 1998-09-16 Vical Incorporated Complex cationic lipids
US5994317A (en) * 1996-04-09 1999-11-30 Vical Incorporated Quaternary cytofectins
JP4087637B2 (ja) 2001-04-23 2008-05-21 信越化学工業株式会社 エステル構造を有する新規第三級アミン化合物及びその製造方法
FR2873376B1 (fr) * 2004-07-23 2006-11-24 Tetrahedron Sas Nouveaux seleno-hydroxyacides et leurs derives, applications en nutrition, cosmetique et pharmacie
CA2841881A1 (en) 2011-07-12 2013-01-17 General Electric Company Polymer and method for removing undesirable elements from aqueous solutions
CN103131227B (zh) 2013-02-23 2015-05-13 北京化工大学 一种抗生物垢涂层的制备方法
WO2014134445A1 (en) * 2013-02-28 2014-09-04 Tufts Unversity Disulfide compounds for delivery of pharmaceutical agents
WO2014186366A1 (en) * 2013-05-13 2014-11-20 Tufts University Nanocomplexes for delivery of saporin
US10888622B2 (en) 2013-05-14 2021-01-12 Trustees Of Tufts College Nanocomplexes of modified peptides or proteins
WO2014210356A1 (en) 2013-06-26 2014-12-31 Massachusetts Institute Of Technology Multi-tailed lipids and uses thereof
EP3170676B1 (en) 2014-07-17 2020-09-09 Toppan Printing Co., Ltd. Thermal transfer image receiving sheet and method for producing same
WO2017176974A1 (en) 2016-04-06 2017-10-12 Ohio State Innovation Foundation Biodegradable amino-ester nanomaterials for nucleic acid delivery
US20190336611A1 (en) 2016-06-09 2019-11-07 Curevac Ag Hybrid carriers for nucleic acid cargo
WO2018022292A1 (en) 2016-07-26 2018-02-01 Trustees Of Tufts College Antibody-conjugated nanoparticles and medical uses thereof
IL276322B2 (en) 2018-02-01 2024-12-01 Tufts College Lipid-like nanocomplexes and uses thereof

Also Published As

Publication number Publication date
MX2020007944A (es) 2020-11-24
IL276322B1 (en) 2024-08-01
JP2021512865A (ja) 2021-05-20
WO2019152848A1 (en) 2019-08-08
AU2019215157B2 (en) 2024-12-19
KR102904334B1 (ko) 2025-12-24
IL276322A (en) 2020-09-30
US20230405022A1 (en) 2023-12-21
JP7497045B2 (ja) 2024-06-10
CA3089826A1 (en) 2019-08-08
EP3746129A4 (en) 2022-03-02
IL276322B2 (en) 2024-12-01
JP2024116162A (ja) 2024-08-27
US20200368254A1 (en) 2020-11-26
MX429255B (es) 2025-11-13
US12133855B2 (en) 2024-11-05
EP3746129A1 (en) 2020-12-09
KR20200115591A (ko) 2020-10-07
JP7650112B2 (ja) 2025-03-24
AU2019215157A1 (en) 2020-08-13
CN111954542A (zh) 2020-11-17

Similar Documents

Publication Publication Date Title
US20230405022A1 (en) Lipid-like nanocomplexes and uses thereof
Yao et al. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery
Chaubey et al. Mannose-conjugated curcumin-chitosan nanoparticles: Efficacy and toxicity assessments against Leishmania donovani
Luo et al. Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer
Mo et al. Intracellular delivery and antitumor effects of pH-sensitive liposomes based on zwitterionic oligopeptide lipids
Siew et al. Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles
US20200003782A1 (en) Nanoparticles for mitochondrial trafficking of agents
Agrawal et al. Bioadhesive micelles of d-α-tocopherol polyethylene glycol succinate 1000: Synergism of chitosan and transferrin in targeted drug delivery
US8277847B2 (en) Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy
Gao et al. Glutathione-responsive nanoparticles based on a sodium alginate derivative for selective release of doxorubicin in tumor cells
CN105283441B (zh) 用于递送药剂的二硫化合物
Cheng et al. pH-sensitive pluronic micelles combined with oxidative stress amplification for enhancing multidrug resistance breast cancer therapy
Xu et al. Functional-segregated coumarin-containing telodendrimer nanocarriers for efficient delivery of SN-38 for colon cancer treatment
JP2008537943A5 (cg-RX-API-DMAC7.html)
Luo et al. Charge convertible biomimetic micellar nanoparticles for enhanced melanoma-targeted therapy through tumor cells and tumor-associated macrophages dual chemotherapy with IDO immunotherapy
Du et al. Reduction-sensitive mixed micelles for selective intracellular drug delivery to tumor cells and reversal of multidrug resistance
US20220280522A1 (en) Telodendrimers with riboflavin moieties and nanocarriers and methods of making and using same
Goldenbogen et al. Reduction-sensitive liposomes from a multifunctional lipid conjugate and natural phospholipids: reduction and release kinetics and cellular uptake
Liu et al. pH-sensitive dual drug loaded janus nanoparticles by oral delivery for multimodal analgesia
Marwah et al. Functionally engineered ‘hepato-liposomes’: Combating liver-stage malaria in a single prophylactic dose
Ding et al. Engineered exosomes improve the effects of curcumin on protecting mitochondria of neurons in Alzheimer's disease
He et al. Dimeric artesunate-choline conjugate micelles coated with hyaluronic acid as a stable, safe and potent alternative anti-malarial injection of artesunate
Fan et al. Reduction-responsive Crosslinked Micellar Nanoassemblies for Tumor-targeted Drug Delivery: Fan et al.
JP2012515774A (ja) 薬剤化合物の溶解性を増加させるpeg−脂質抱合体
Joshi et al. Development and Characterization of Liposomal formulation for ophthalmic delivery of Prednisolone Acetate

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements